A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Trial Profile

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms STRENGTH
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 29 Nov 2019 to 31 Oct 2019.
    • 03 Nov 2017 Planned primary completion date changed from 29 Nov 2019 to 31 Oct 2019.
    • 12 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top